Management of Oligodendroglioma Patients

Oligodendroglioma is a neuroepithelial tissue tumor of glioma type and responds well to chemotherapy. Oligodendroglioma tends to invade leptomeninges. Further metastases of cerebrospinal fluid occur in 1-2% of cases. The prognosis of patients with oligodendroglioma is varied, depending on the grade...

Full description

Saved in:
Bibliographic Details
Main Authors: Muhammad Miftahussurur, Ugroseno, Amie Vidyani
Format: Book Section PeerReviewed
Language:English
English
English
Published: SCITEPREES-Science and Technology Publications, Lda. 2017
Subjects:
Online Access:http://repository.unair.ac.id/92037/1/16.%20management%20of%20oligo.pdf
http://repository.unair.ac.id/92037/2/16p.%20Management%20of%20Oligodendroglioma%20Patients.pdf
http://repository.unair.ac.id/92037/5/oligodendroglioma.pdf
http://repository.unair.ac.id/92037/
https://www.scitepress.org/PublicationsDetail.aspx?ID=kPyFR99PD9o=&t=1
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universitas Airlangga
Language: English
English
English
Description
Summary:Oligodendroglioma is a neuroepithelial tissue tumor of glioma type and responds well to chemotherapy. Oligodendroglioma tends to invade leptomeninges. Further metastases of cerebrospinal fluid occur in 1-2% of cases. The prognosis of patients with oligodendroglioma is varied, depending on the grade they are experiencing. Progression to anaplasia may occur, even though the frequency is lower than astrocytoma. The diagnosis of oligodendroglioma is based on light microscope examination, and is often difficult to distinguish from astrocytoma. A case of a low-grade oligodendroglioma patient is reported. Special attention is required in this grade, as it can progress slowly but progressively with manifestations only in the form of partial seizures that occur for years. The diagnosis is based on several clinical, radiological signs and is supported by anatomical pathology examination. This patient was given temozolomide (TMZ) chemotherapy for 6 cycles and radiotherapy after resection surgery . The patient survived until 28 months without tumor residue or a new tumor.